List of Promacta Kit drug patents
Promacta Kit is owned by Novartis.
Promacta Kit contains Eltrombopag Olamine.
Promacta Kit has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Promacta Kit are:
- US7160870*PED
- US7795293
- US7160870
Promacta Kit was authorised for market use on 24 August, 2015.
Promacta Kit is available in for suspension;oral dosage forms.
Promacta Kit can be used as treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp), patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia; treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy, treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.
The generics of Promacta Kit are possible to be released after 13 January, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(6 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(19 days ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(18 days ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(5 months from now) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis...
Dosage: FOR SUSPENSION;ORAL
PROMACTA KIT family patents
23
United States
5
Hong Kong
5
China
5
Germany
5
European Union
4
Slovenia
4
Korea, Republic of
4
Japan
4
Denmark
4
Spain
4
Norway
4
Portugal
3
Poland
3
Argentina
3
Hungary
3
New Zealand
3
Australia
3
Austria
3
Israel
3
Cyprus
2
Canada
2
Brazil
2
Taiwan
2
Malaysia
2
Mexico
2
South Africa
1
Luxembourg
1
Lithuania
1
Iceland
1
Belgium
1
Czech Republic
1
Russia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic